The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
06 03 2021
Historique:
received: 31 01 2021
revised: 25 02 2021
accepted: 01 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 20 4 2021
Statut: epublish

Résumé

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is the cause of a worldwide pandemic, currently with limited therapeutic options. The spike glycoprotein and envelope protein of SARS-CoV-2, containing disulfide bridges for stabilization, represent an attractive target as they are essential for binding to the ACE2 receptor in host cells present in the nasal mucosa. Bromelain and Acetylcysteine (BromAc) has synergistic action against glycoproteins by breakage of glycosidic linkages and disulfide bonds. We sought to determine the effect of BromAc on the spike and envelope proteins and its potential to reduce infectivity in host cells. Recombinant spike and envelope SARS-CoV-2 proteins were disrupted by BromAc. Spike and envelope protein disulfide bonds were reduced by Acetylcysteine. In in vitro whole virus culture of both wild-type and spike mutants, SARS-CoV-2 demonstrated a concentration-dependent inactivation from BromAc treatment but not from single agents. Clinical testing through nasal administration in patients with early SARS-CoV-2 infection is imminent.

Identifiants

pubmed: 33800932
pii: v13030425
doi: 10.3390/v13030425
pmc: PMC7999995
pii:
doi:

Substances chimiques

Antiviral Agents 0
Spike Glycoprotein, Coronavirus 0
Bromelains 9001-00-7
Acetylcysteine WYQ7N0BPYC

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Mucpharm pty ltd
ID : COVID research

Références

Respir Res. 2017 Jan 24;18(1):26
pubmed: 28118826
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
J Biol Chem. 1973 Jan 25;248(2):707-10
pubmed: 4734333
Emerg Microbes Infect. 2020 Dec;9(1):601-604
pubmed: 32178593
Biomed Pharmacother. 2018 Jul;103:1-8
pubmed: 29635121
Science. 2020 Jul 17;369(6501):330-333
pubmed: 32366695
Can J Comp Med. 1977 Jan;41(1):122-6
pubmed: 832184
Anticancer Res. 2016 Jun;36(6):3224-5
pubmed: 27272863
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Int J Infect Dis. 2020 Apr;93:268-276
pubmed: 32081774
Nat New Biol. 1971 Jan 27;229(4):114-6
pubmed: 5283617
Clin Otolaryngol Allied Sci. 1999 Feb;24(1):67-8
pubmed: 10196653
Int J Cancer. 2014 Jan 15;134(2):478-86
pubmed: 23843173
Nanoscale. 2020 Aug 21;12(31):16409-16413
pubmed: 32725017
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Materials (Basel). 2020 Nov 26;13(23):
pubmed: 33255977
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
Int J Antimicrob Agents. 2020 Aug;56(2):106080
pubmed: 32634603
Protein J. 2020 Dec;39(6):644-656
pubmed: 33106987
Am J Transl Res. 2020 Nov 15;12(11):7404-7419
pubmed: 33312377
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Clin Transl Med. 2021 Feb;11(2):e281
pubmed: 33635001
Virol J. 2019 May 27;16(1):69
pubmed: 31133031
FASEB J. 2020 Oct;34(10):13185-13193
pubmed: 32780893
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Eur J Surg Oncol. 2021 Jan;47(1):115-122
pubmed: 31679953
Biosci Rep. 1991 Oct;11(5):243-55
pubmed: 1724188
EMBO J. 2005 Apr 20;24(8):1634-43
pubmed: 15791205
J Gen Virol. 1974 May;23(2):129-43
pubmed: 4208869
Science. 2020 Sep 25;369(6511):1586-1592
pubmed: 32694201
Emerg Microbes Infect. 2020 Dec;9(1):837-842
pubmed: 32301390
Nat Commun. 2021 Jan 11;12(1):249
pubmed: 33431872
JAMA Otolaryngol Head Neck Surg. 2020 Sep 17;:
pubmed: 32940656
Expert Opin Ther Targets. 2016;20(1):123-43
pubmed: 26178644
iScience. 2020 Jun 26;23(6):101212
pubmed: 32512386
Antiviral Res. 2020 Apr;176:104742
pubmed: 32057769
J Biol Chem. 2006 Apr 7;281(14):9200-4
pubmed: 16418166
Pleura Peritoneum. 2017 Jun 1;2(2):111-117
pubmed: 30911639
ACS Omega. 2020 Jun 23;5(26):16292-16298
pubmed: 32656452
Medicine (Baltimore). 2018 Nov;97(45):e13087
pubmed: 30407312
Mol Ther. 2011 Nov;19(11):1981-9
pubmed: 21829177
Biosci Rep. 1993 Dec;13(6):333-47
pubmed: 8204803
ACS Cent Sci. 2020 Oct 28;6(10):1722-1734
pubmed: 33140034
Nature. 2020 Sep;585(7826):588-590
pubmed: 32698190
Proc Natl Acad Sci U S A. 1994 May 10;91(10):4559-63
pubmed: 8183947
Curr Biol. 2020 Jun 8;30(11):2196-2203.e3
pubmed: 32416074
World J Virol. 2016 May 12;5(2):38-62
pubmed: 27175349

Auteurs

Javed Akhter (J)

Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.
Mucpharm Pty Ltd., Sydney, NSW 2217, Australia.

Grégory Quéromès (G)

CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.

Krishna Pillai (K)

Mucpharm Pty Ltd., Sydney, NSW 2217, Australia.

Vahan Kepenekian (V)

Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.
Hospices Civils de Lyon, EMR 3738 (CICLY), Lyon 1 Université, F-69921 Lyon, France.

Samina Badar (S)

Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.
St. George & Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia.

Ahmed H Mekkawy (AH)

Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.
Mucpharm Pty Ltd., Sydney, NSW 2217, Australia.
St. George & Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia.

Emilie Frobert (E)

CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.
Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, Groupement Hospitalier Nord, F-69004 Lyon, France.

Sarah J Valle (SJ)

Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.
Mucpharm Pty Ltd., Sydney, NSW 2217, Australia.
St. George & Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia.

David L Morris (DL)

Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.
Mucpharm Pty Ltd., Sydney, NSW 2217, Australia.
St. George & Sutherland Clinical School, University of New South Wales, Sydney, NSW 2217, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH